Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC cut its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 1.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 877,760 shares of the biotechnology company's stock after selling 12,047 shares during the quarter. Fisher Asset Management LLC owned about 1.13% of Veracyte worth $29,879,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of VCYT. Vanguard Group Inc. increased its stake in Veracyte by 3.7% in the first quarter. Vanguard Group Inc. now owns 7,384,871 shares of the biotechnology company's stock valued at $163,649,000 after purchasing an additional 266,660 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Veracyte by 6.9% in the first quarter. CANADA LIFE ASSURANCE Co now owns 8,198 shares of the biotechnology company's stock valued at $182,000 after acquiring an additional 530 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Veracyte by 105.6% in the first quarter. Lazard Asset Management LLC now owns 6,368 shares of the biotechnology company's stock valued at $140,000 after acquiring an additional 3,271 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Veracyte by 11.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 41,041 shares of the biotechnology company's stock valued at $910,000 after acquiring an additional 4,256 shares in the last quarter. Finally, Burney Co. boosted its holdings in shares of Veracyte by 38.0% in the first quarter. Burney Co. now owns 26,063 shares of the biotechnology company's stock valued at $578,000 after acquiring an additional 7,176 shares in the last quarter.

Veracyte Stock Performance

Shares of VCYT opened at $42.84 on Wednesday. The company has a 50-day moving average of $35.21 and a two-hundred day moving average of $28.65. Veracyte, Inc. has a 12-month low of $18.61 and a 12-month high of $42.86.

Veracyte (NASDAQ:VCYT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.16. The company had revenue of $115.86 million during the quarter, compared to analysts' expectations of $109.81 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The firm's quarterly revenue was up 28.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.03) earnings per share. On average, equities research analysts expect that Veracyte, Inc. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

VCYT has been the topic of several analyst reports. Scotiabank lifted their target price on shares of Veracyte from $40.00 to $44.00 and gave the company a "sector outperform" rating in a report on Friday, November 8th. Guggenheim initiated coverage on shares of Veracyte in a report on Thursday, October 10th. They issued a "buy" rating and a $40.00 target price on the stock. UBS Group lifted their target price on shares of Veracyte from $43.00 to $46.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Wolfe Research began coverage on shares of Veracyte in a report on Friday, November 15th. They set an "outperform" rating and a $50.00 price objective on the stock. Finally, Morgan Stanley boosted their price objective on shares of Veracyte from $26.00 to $28.00 and gave the stock an "underweight" rating in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $41.25.

Insiders Place Their Bets

In other news, Director Evan/ Fa Jones sold 5,173 shares of the business's stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $35.23, for a total value of $182,244.79. Following the completion of the transaction, the director now owns 34,343 shares of the company's stock, valued at $1,209,903.89. The trade was a 13.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John Leite sold 5,479 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $29.78, for a total transaction of $163,164.62. Following the completion of the transaction, the insider now directly owns 76,174 shares of the company's stock, valued at approximately $2,268,461.72. This represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Veracyte Company Profile

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.